|
Appointment of Wonsuk Lee as CEO and President
2023.01.03
|
|---|
|
Wonsuk Lee was inaugurated as CEO and President of Daehan Nupharm on January 2. Born in 1977, he joined the company in 2004, progressing through roles in the overseas business team, finance team, and management team, and most recently served as Vice President of the Management Headquarters.
At the inauguration ceremony held together with the 2023 kick-off meeting, he was awarded the Long-term Service Award and the Daehan Nupharm Person of the Year Award. In his inaugural speech, he outlined future management policies centered on the keywords “listening,” “action,” and “responsibility.”
Daehan Nupharm is a pharmaceutical and veterinary medicine manufacturer and distributor focused on developing biopharmaceuticals and improved new drugs. The company plans to launch a variety of pharmaceuticals and health supplements, including ‘Zero-Be’ tablets that improve dosing convenience and ‘Cambel Double’ tablets, which are twice the dosage of the 'Cambel' herbal formula.
The company has also been preparing for pet product development for several years and aims to release eight items this year. It is strengthening R&D for new drug development, having completed the Industry-Academia-Research Center in the Second Pangyo Techno Valley in 2021. The center is designed to improve work efficiency and welfare through the keywords “research and development” and “communication.”
In his speech, Lee emphasized creating synergies between the human pharmaceuticals, veterinary medicines, and health supplements divisions by newly establishing a Future Business Division and strengthening pipelines across divisions. He expressed his commitment to building a workplace where employees are proud to belong to Daehan Nupharm and rewarded for their achievements as the company grows into a global pharmaceutical and bio company. |


Home